Axalbion is a clinical-stage pharmaceutical company developing TRPM8 agonists for the treatment of chronic cough and dry eyes, two chronic, common and debilitating disorders, with limited treatment options.
Investors 1
| Date | Name | Website |
| 22.05.2024 | Irrus Inve... | irrusinves... |
Mentions in press and media 1
| Date | Title | Description |
| 29.06.2022 | Axalbion Announces Positive Findings from Phase 2 Clinical Study in Chronic Cough with AX-8, a Novel TRPM8 Agonist | AX-8 reduces cough frequency and improves patient-reported outcomes in patients with chronic cough MANCHESTER, England & MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–June 29, 2022– Axalbion, a clinical-stage biopharmaceutical company focused o... |